CervoMed (CRVO) announced that initial results from its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia, have been accepted for a late-breaking oral presentation at an upcoming international medical conference.
Key Details
- Event: The presentation will highlight 12-week biomarker data for neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) from at least 22 of the 25 trial participants.
- Conference: The results will be presented at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia, PA, taking place from October 8-11, 2026.
- Indication Context: nfvPPA is a rare brain disorder with no currently approved treatments in the United States or the European Union.